ClinicalTrials.gg

Program

Olanzapine

Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.

Furthest: phase 4, since Apr 30, 200254 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly360 open or runningphase 4since Apr 30, 2002Apr 30, 2002none ahead
Viatris50 open or runningphase 4since Oct 12, 2005Sep 1, 2005none ahead
Dr. Reddy's Laboratories40 open or runningphase 1since Jan 2, 2012Jan 2, 2012none ahead
Abbott20 open or runningphase 4since Oct 16, 2003Oct 16, 2003none ahead
AstraZeneca10 open or runningphase 3since May 2, 2002May 2, 2002none ahead
HK inno.N10 open or runningphase 4since May 11, 2014May 11, 2014none ahead
joint-stock-company-farmak10 open or runningphase 1since Nov 15, 2021Nov 15, 2021none ahead
neurelis-inc10 open or runningphase 1since Sep 6, 2024Sep 6, 2024none ahead
orexigen-therapeutics-inc10 open or runningphase 2since Aug 12, 2008Aug 12, 2008none ahead
Qilu Pharmaceutical10 open or runningphase 3since Mar 27, 2023Mar 27, 2023none ahead
Teva Pharmaceutical Industries10 open or runningphase 1since Mar 13, 2024Mar 13, 2024none ahead

Also a collaborator on its studies: Pfizer and H. Lundbeck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Apr 30, 2002.

  1. Feb 8, 2008Phase 3 study in Bipolar I DisorderEli Lilly · NCT00618748 · 101 enrolled · Japan
  2. Mar 18, 2008Phase 3 study in SchizophreniaEli Lilly · NCT00640510 · 34 enrolled · Japan
  3. Mar 30, 20083 phase 1 studies in HealthyViatris · NCT00648921, NCT00647972, NCT00647777
  4. Aug 12, 2008orexigen-therapeutics-inc's first study: phase 2 study in SchizophreniaNew to orexigen-therapeutics-incorexigen-therapeutics-inc · NCT00734435 · 26 enrolled · United States
  5. Oct 3, 2008Phase 4 study in Bipolar DisorderEli Lilly · NCT00767715 · 11 enrolled · Sweden
  6. Aug 12, 2009Phase 3 study in Depressive Disorder, Treatment-ResistantEli Lilly · NCT00958568 · 892 enrolled · United States, Argentina, India and more
  7. Sep 1, 2009Phase 3 study in SchizophreniaEli Lilly · NCT00970281 · 91 enrolled · Japan
  8. Jan 2, 2012Dr. Reddy's Laboratories's first studies: 4 phase 1 studiesNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01503450, NCT01503437, NCT01503424 and 1 more
  9. Sep 7, 2012Phase 3 study in Depressive Disorder, Treatment-ResistantEli Lilly · NCT01687478 · 176 enrolled · China
  10. May 11, 2014HK inno.N's first study: phase 4 study in SchizophreniaNew to HK inno.NHK inno.N · NCT02137993 · 64 enrolled
  11. Nov 15, 2021joint-stock-company-farmak's first study: phase 1 study in PharmacokineticsNew to joint-stock-company-farmakjoint-stock-company-farmak · NCT05123976 · 32 enrolled · Czechia
  12. Mar 27, 2023Qilu Pharmaceutical's first study: phase 3 study in Acute AgitationNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT05803642 · 318 enrolled
  13. Mar 13, 2024Teva Pharmaceutical Industries's first study: phase 1 study in SchizophreniaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06319170 · 106 enrolled · United States
  14. Sep 6, 2024neurelis-inc's first study: phase 1 study in HealthyNew to neurelis-incneurelis-inc · NCT06600477 · 24 enrolled · Jordan

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule

Studies

All 54 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06600477Healthy · Jordan1Completedneurelis-incNov 1, 202324
NCT06319170Schizophrenia · United States1CompletedTeva Pharmaceutical IndustriesJan 15, 2025106
NCT05803642Acute Agitation3UNKNOWNQilu PharmaceuticalMay 7, 2024318
NCT05123976Pharmacokinetics · Czechia1Completedjoint-stock-company-farmakNov 30, 202032
NCT02137993Schizophrenia4CompletedHK inno.NMay 201364
NCT01687478Depressive Disorder, Treatment-Resistant · China3TerminatedEli LillyNov 2015176
NCT01503450Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedDr. Reddy's LaboratoriesDec 200626
NCT01503437Fasting · India1CompletedDr. Reddy's LaboratoriesNov 200622
NCT01503424Lecithin Cholesterol Acyltransferase Deficiency · India1CompletedDr. Reddy's LaboratoriesSep 201148
NCT01503398Fasting · India1CompletedDr. Reddy's LaboratoriesSep 201148
NCT00970281Schizophrenia · Japan3CompletedEli LillyApr 201191
NCT00958568Depressive Disorder, Treatment-Resistant · United States, Argentina, India and more3CompletedEli LillyMar 2012892
NCT00767715Bipolar Disorder · Sweden4TerminatedEli LillyApr 200511
NCT00734435Schizophrenia · United States2Terminatedorexigen-therapeutics-incDec 200826
NCT00648921Healthy · United States1CompletedViatrisJul 200330
NCT00647972Healthy · United States1TerminatedViatrisMay 200332
NCT00647777Healthy · United States1CompletedViatrisJul 200332
NCT00640510Schizophrenia · Japan3CompletedEli LillyJul 200834
NCT00618748Bipolar I Disorder · Japan3CompletedEli LillySep 2010101
NCT00510146Bipolar Disorder · China, Japan, Korea, Republic of3CompletedEli LillyMar 2010514
NCT00485771Bipolar Disorder · United States4CompletedEli Lilly403
NCT00402324Bipolar I Disorder · United States4CompletedEli LillyFeb 2008202
NCT00401973Schizophrenia · United States, Brazil, Israel and more3CompletedEli LillySep 2008199
NCT00347425Schizophrenia · United States, Argentina, Canada and more3CompletedAbbottFeb 2008286
NCT00337662Schizophrenia · United States, Argentina, Russian Federation4CompletedEli LillyDec 2007628
NCT00303602Schizophrenia · United States, Canada, Mexico and more4CompletedEli LillyDec 2007149
NCT00266630Mania · Japan3CompletedEli LillyMay 2009139
NCT00259272Bipolar Disorder I or II · France3CompletedEli LillyMay 2008141
NCT00239109Schizophrenia · Spain4CompletedViatris112
NCT00191997Bipolar Disorder · Spain4CompletedEli Lilly180
NCT00191828Weight Gain · Italy4CompletedEli Lilly60
NCT00191555Schizophrenia · France4CompletedEli Lilly360
NCT00190892Bipolar Disorder · Australia, Greece, Hungary and more4CompletedEli Lilly120
NCT00190749Schizophrenia · United States4CompletedEli LillyJun 2008130
NCT00145444Schizophrenia · Belgium, Netherlands3CompletedViatris100
NCT00129220Bipolar Disorder · Japan3CompletedEli LillyJan 2009224
NCT00113594Schizophrenia · United States, Puerto Rico, Russian Federation3CompletedEli Lilly100
NCT00103571Schizophrenia · United States, Puerto Rico4CompletedEli Lilly600
NCT00100776Schizophrenia · United States4CompletedEli Lilly600
NCT00094549Bipolar Disorder · United States, Lithuania, Puerto Rico and more4CompletedEli Lilly500
NCT00091650Borderline Personality Disorder · United States, Belgium, France and more3CompletedEli Lilly300
NCT00090012Schizophrenia · United States4CompletedEli Lilly340
NCT00088491Schizophrenia · Finland, Turkey3CompletedEli Lilly1,205
NCT00088465Schizophrenia · United States, Argentina, Australia and more3CompletedEli LillyDec 2010931
NCT00088049Schizophrenia · United States4CompletedEli Lilly560
NCT00088036Borderline Personality Disorder · United States, Argentina, Poland and more3CompletedEli Lilly450
NCT00071253Bipolar Disorder · United States4TerminatedAbbott180
NCT00051298Schizophrenia · United States, Russian Federation3CompletedEli Lilly107
NCT00050206Bipolar Disorder · United States4CompletedEli Lilly130
NCT00036088Schizophrenia · United States, Argentina, Austria and more4CompletedEli Lilly530
NCT00035321Depressive Disorder, Major · United States, Canada3CompletedEli Lilly600
NCT00034892Schizophrenia · United States, Canada3CompletedAstraZenecaMar 2005
NCT00034801Depression · United States4CompletedEli Lilly378
NCT00034580Bipolar Disorder · United States4CompletedEli Lilly326

How it is read

Names in the registry

  • “Olanzapine”, 33 entries
  • “olanzapine”, 17 entries
  • “ALKS 3831”, 7 entries
  • “Olanzapine Tablets 5 mg”, 2 entries
  • “Olanzapine OD Tablets 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.